Sionna Therapeutics, Inc. (SION) Price & Analysis

Compare

26 Followers

SION Stock Chart & Stats

$36.81

Market closed

$36.81

Day’s Range― - ―

52-Week Range$7.26 - $45.00

Previous CloseN/A

VolumeN/A

Average Volume (3M)301.86K

Market Cap

$1.84B

Enterprise Value$1.07B

Total Cash (Recent Filing)$248.33M

Total Debt (Recent Filing)$8.97M

Price to Earnings (P/E)―

Beta1.06

Next Earnings

Mar 19, 2026

EPS Estimate

-0.54

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.46

Shares Outstanding44,628,788

10 Day Avg. Volume294,859

30 Day Avg. Volume301,861

Financial Highlights & Ratios

PEG Ratio-0.59

Price to Book (P/B)-6.74

Price to Sales (P/S)0.00

P/FCF Ratio-20.89

Enterprise Value/Market Cap0.58

Enterprise Value/RevenueN/A

Enterprise Value/Gross Profit-4.33K

Enterprise Value/Ebitda-14.19

Forecast

1Y Price Target

$47.80

Price Target Upside29.86% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering6

EPS Forecast (FY)-2.25

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Clinical Advancement And Financial RunwayAnalyst points out that IND clearance, progression into later-stage studies, and a multi-year cash runway support continued development of Sionna's lead programs toward upcoming clinical milestones.

Mechanism Of Action (NBD1 Targeting)Analyst highlights that Sionna's NBD1-targeting candidates restored CFTR function in preclinical studies, offering a mechanistic approach that could produce meaningful improvements beyond current modulators.

Translational Biomarker ValidationAnalyst notes that Sionna's CF HBE assay, calibrated to industry standards, functions as a translational proof-of-concept that helps guide dosing and increases the probability of clinical success.

Bears Say

Patient Adoption RiskAnalyst warns that the requirement for monthly liver-function monitoring to switch therapies has slowed uptake for some families, signaling broader patient and caregiver reluctance that could constrain adoption of new cystic fibrosis treatments.

Sionna Therapeutics, Inc. News

Sionna Therapeutics price target raised to $58 from $50 at BTIG

BTIG raised the firm’s price target on Sionna Therapeutics (SION) to $58 from $50 and keeps a Buy...

8d ago

SION

VRTX

Sionna Therapeutics price target raised to $58 from $50 at BTIG

BTIG analyst Kambiz Yazdi raised the firm’s price target on Sionna Therapeutics (SION) to $58 from $50 and...

9d ago

SION

Coty downgraded, Spruce Biosciences initiated: Wall Street’s top analyst calls

The most talked about and market moving research calls around Wall Street are now in one place. Here...

24d ago

AME

Sionna Therapeutics initiated with an Outperform at LifeSci Capital

LifeSci Capital analyst Cory Jubinville initiated coverage of Sionna Therapeutics (SION) with an Outperform rating and $60 price...

24d ago

SION

Multiple Shots on Goal in Cystic Fibrosis: Sionna’s NBD1-Targeted Pipeline and 2026 Clinical Readouts Drive Buy Thesis and $58 DCF-Based Target

Analyst Kambiz Yazdi from BTIG maintained a Buy rating on Sionna Therapeutics, Inc. and keeping the price target...

2d ago

SION

Sionna Therapeutics: NBD1-Targeted CFTR Stabilization Strategy Positions Pipeline for Best-in-Class Efficacy and Blockbuster Upside in Cystic Fibrosis

Cory Jubinville, PhD, an analyst from LifeSci Capital, has initiated a new Buy rating on Sionna Therapeutics, Inc....

24d ago

SION

Midday Fly By: Nvidia invests in Synopsys, U.S. strikes pharma deal with UK

The major averages were broadly lower near noon, starting the month in the red as investors await fresh...

2M ago

Sionna downgraded to Underperform from Sector Perform at RBC Capital

RBC Capital downgraded Sionna Therapeutics (SION) to Underperform from Sector Perform with an unchanged price target of $24....

2M ago

SION

BTIG Assigns Buy Rating to Sionna Therapeutics, Citing Innovative Cystic Fibrosis Therapies and Strong Market Potential

, an analyst from BTIG, has initiated a new Buy rating on Sionna Therapeutics, Inc. (SION). BTIG has...

2M ago

SION

Sionna Therapeutics initiated with a Buy at BTIG

BTIG analyst Kambiz Yazdi initiated coverage of Sionna Therapeutics (SION) with a Buy rating and $50 price target...

2M ago

SION

Sionna Therapeutics: Promising Developments and Strategic Advancements Boost Price Target

JonesTrading analyst Debanjana Chatterjee has reiterated their bullish stance on SION stock, giving a Buy rating on November...

2M ago

SION

Sionna Therapeutics Advances CF Pipeline Amid Strong Financials

Sionna Therapeutics, Inc. ( ($SION) ) has released its Q3 earnings. Here is a breakdown of the information...

2M ago

SION

Sionna Therapeutics reports Q3 EPS (46c), consensus (47c)

“We maintain our track record of strong execution, achieving substantial progress across our pipeline in the third quarter....

2M ago

SION

Sionna Therapeutics expects cash to fund operations into 2028

Maintained strong cash position with approximately $325.0 million in cash and cash equivalents, expected to fund operations into...

2M ago

SION

SION FAQ

What was Sionna Therapeutics, Inc.’s price range in the past 12 months?

Sionna Therapeutics, Inc. lowest stock price was $7.25 and its highest was $45.00 in the past 12 months.

What is Sionna Therapeutics, Inc.’s market cap?

Sionna Therapeutics, Inc.’s market cap is $1.84B.

When is Sionna Therapeutics, Inc.’s upcoming earnings report date?

Sionna Therapeutics, Inc.’s upcoming earnings report date is Mar 19, 2026 which is in 62 days.

How were Sionna Therapeutics, Inc.’s earnings last quarter?

Sionna Therapeutics, Inc. released its earnings results on Nov 05, 2025. The company reported -$0.46 earnings per share for the quarter, beating the consensus estimate of -$0.484 by $0.024.

Is Sionna Therapeutics, Inc. overvalued?

According to Wall Street analysts Sionna Therapeutics, Inc.’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Sionna Therapeutics, Inc. pay dividends?

Sionna Therapeutics, Inc. does not currently pay dividends.

What is Sionna Therapeutics, Inc.’s EPS estimate?

Sionna Therapeutics, Inc.’s EPS estimate is -0.54.

How many shares outstanding does Sionna Therapeutics, Inc. have?

Sionna Therapeutics, Inc. has 44,628,788 shares outstanding.

What happened to Sionna Therapeutics, Inc.’s price movement after its last earnings report?

Sionna Therapeutics, Inc. reported an EPS of -$0.46 in its last earnings report, beating expectations of -$0.484. Following the earnings report the stock price went down -1.571%.

Which hedge fund is a major shareholder of Sionna Therapeutics, Inc.?

Currently, no hedge funds are holding shares in SION

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Sionna Therapeutics, Inc. Stock Smart Score

Underperform

Fundamentals

Return on Equity

-28.07%

Trailing 12-Months

Asset Growth

71.99%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Sionna Therapeutics, Inc.

Sionna Therapeutics, Inc. is a biopharmaceutical company. The Company provides treatment paradigm for cystic fibrosis patients by developing medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator.

Sionna Therapeutics, Inc. (SION) Earnings & Revenues

Historic Earnings Reports

SION Stock 12 Month Forecast

Average Price Target

$47.80

▲(29.86% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"9":"$9","22":"$22","35":"$35","48":"$48","61":"$61"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":60,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$60.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":47.8,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$47.80</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":24,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$24.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[9,22,35,48,61],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Mar<br/>2025","6":"May<br/>2025","9":"Oct<br/>2025","12":"Jan<br/>2026","25":"Jan<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,41.14,42.59076923076923,44.041538461538465,45.49230769230769,46.94307692307692,48.393846153846155,49.84461538461539,51.29538461538462,52.746153846153845,54.19692307692308,55.64769230769231,57.098461538461535,58.549230769230775,{"y":60,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,41.14,41.652307692307694,42.16461538461539,42.676923076923075,43.18923076923077,43.70153846153846,44.213846153846156,44.72615384615384,45.238461538461536,45.75076923076923,46.26307692307692,46.77538461538461,47.2876923076923,{"y":47.8,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,41.14,39.82153846153846,38.503076923076925,37.184615384615384,35.86615384615385,34.54769230769231,33.22923076923077,31.91076923076923,30.592307692307692,29.273846153846154,27.955384615384617,26.636923076923075,25.318461538461538,{"y":24,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":22.24,"date":1733011200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":22.24,"date":1735689600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":22.24,"date":1738368000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":13.77,"date":1740787200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":13.77,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.16,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.9,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.92,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.39,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28.47,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":38.21,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":38.96,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":41.14,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >